Adjuvant therapy of breast cancer

Minerva Ginecologica

Volumn 57, Issue 5, 2005, Pages 521-536

  Kaklamani, V G ^a   Gradishar, W J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Breast neoplasms; Chemotherapy, hormonal replacement therapy; Endocrine ablation

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TRIPTORELIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTHRALGIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG FATALITY; DRUG INDICATION; ESTROGEN SYNTHESIS; FEBRILE NEUTROPENIA; FRACTURE; GONADORELIN RELEASE; GRANULOCYTOPENIA; HEART DISEASE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LONG TERM CARE; MUSCULOSKELETAL DISEASE; ONCOGENE NEU; OSTEOPOROSIS; OVARIECTOMY; PREMENOPAUSE; PULSATILE HORMONE RELEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS;

EID: 27844514134     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
2. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93: 979-89.
3. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
4. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins NJ, Fechrenbacher L et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 2003;22:12.
5. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
6. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002;8:1073-9.
7. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Kerbrat P et al. Five years analysis of the PACS01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for teh adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004;88 Suppl 1:S16.
8. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. San Antonio Breast Cancer Symposium, 2003, December 3-6, San Antonio, TX.
9. Skipper HE. Laboratory models: some historical perspectives. Cancer Treat Rep 1986;70:3-7.
10. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;3 Suppl:30-5.
11. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
13. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
14. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
15. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
16. Geyer CE, Bryant J, Romond E, Tan-Chiu E, Ewer M, Keefe D et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), Her-2 overexpressing breast cancer (HER-2 + BC). Breast Cancer Res Treat 2004;82 Suppl 1:S13.
17. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
18. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 2001;30: 56-61.
19. Goss P, Grynpas M, Qi S, Hu H. The effects of exemestane on bone and lipids in the ovariectemized rat. Breast Cancer Res Treatment 2001;69:224.
20. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94.
21. Group AT. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res Treatment 2001;69:210.
22. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000-11.
23. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66.
24. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-411.
25. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
26. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67.
27. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359: 2131-9.
28. Group TAT. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treatment 2002;76:12.
29. th Annual San Antonio Breast Cancer Symposium; 2004, December 8-11, San Antonio, TX.
30. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21:2597-9.
31. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Caroti C et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001;19:4209-15.
32. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massabrio M, Porpiglia M et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82 Suppl 1:S6.
33. Jakesz R, Kaufmann M, Gnant M, Jonat W, Mittlboeck M, Greil R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrazole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in teh ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;88 Suppl 1:S7.
34. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
35. Coombes RC, Hall E, Snowdon CF, Bliss JM. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004;88 Suppl 1:S7 (abstract 3).
36. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
37. Goss P, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al. Updated analysis of the NCIC CTG MA. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 2004;22:14S.
38. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-7.
39. Nicholson RI, Walker KJ, Walker RF, Read GF, Turkes A, Robertson JF et al. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer. Horm Res 1989;32 Suppl 1:198-201.
40. Roche H, Mihura J, de Lafontan B et al. Castration and tamoxifen vs chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: a randomized trial with a 7 years follow-up. Proc Am Soc Clin Oncol 1996;15:134.
41. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-11.
42. Arriagada R, Le GM, Spielmann M, Mauriac L, Bonneterre J, Namer M et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Proc Am Soc Clin Oncol 2003;22:14.
43. Davidson N, O'Neill A, Vukov A, Osborne CK, Martino S, White D et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188,INT-0101). Proc Am Soc Clin Oncol 2003;22:15.
44. Robert NJ, Wang M, Cella D, Martino S, Tripathy D, Ingle JN et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer? 3 cm. Proc Am Soc Clin Oncol 2003;22:16.